Company intelligence / Profile preview

Prothya Biosolutions

Ownership: Private
Employees: ~646
Development stage: Commercial

Overview

Prothya Biosolutions produces commercial plasma-derived medicines such as Cofact, Nanogam, and Albuman. The company also has clinical-stage programs including human apotransferrin for congenital atransferrinemia in Phase III trials. It processes around three million liters of plasma annually for international partners.

Therapeutic areas: OtherHematologyImmunologyRare Diseases
Modalities: ProteinPlasma-derived medicinal productsRecombinant protein
Industry: Biotech

Drug pipeline

5 assets

Nanogam

4 more assets in the full pipeline.

Request access →

Partnerships

Erasmus MC and other academic collaborators on clinical studies/programs

Beyond the preview

Go deeper on Prothya Biosolutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prothya Biosolutions.

Explore the full profile